Literature DB >> 29416918

MicroRNA-149 sensitizes colorectal cancer to radiotherapy by downregulating human epididymis protein 4.

Liang-Pan Shi1, Hai-Lian Guo2, Yi-Bin Su1, Zhi-Hua Zheng1, Jiang-Rui Liu1, Shu-Hua Lai3.   

Abstract

Human epididymis protein 4 (HE4) was significantly up-regulated in colorectal cancer (CRC), while the potential relevance to radiation resistance of this phenomenon is still elusive. Relative expressions of target genes were quantified by real-time PCR. The protein level was determined by Western blot. The regulatory effect of miR-149 on WFDC2 (gene encoding HE4 protein) expression was analyzed by luciferase reporter assay. The response to radiation was evaluated by clonogenic assay in vitro and xenograft growth in vivo. WFDC2 was aberrantly up-regulated and miR-149 was down-regulated in CRC. MiR-149 repressed WFDC2 expression via directly targeting its 3'UTR region. The ectopic expression of miR-149 significantly sensitized CRC to radiation both in vitro and in vivo. Likewise, we further demonstrated that WFDC2-deficiency remarkably improved the radiation resistance in CRC. Simultaneously, WFDC2 rescue completely abolished the radiation sensitivity imposed by miR-149. Our data suggested that miR-149 sensitized CRC to radiation via directly inhibiting WFDC2/HE4, which would hold great promise for future therapeutic exploitations.

Entities:  

Keywords:  Colorectal cancer; WFDC2; miR-149; radiation resistance; xenograft

Year:  2018        PMID: 29416918      PMCID: PMC5794719     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  25 in total

Review 1.  The functions of animal microRNAs.

Authors:  Victor Ambros
Journal:  Nature       Date:  2004-09-16       Impact factor: 49.962

2.  A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors.

Authors:  C Kirchhoff; I Habben; R Ivell; N Krull
Journal:  Biol Reprod       Date:  1991-08       Impact factor: 4.285

Review 3.  Colorectal cancer.

Authors:  David Cunningham; Wendy Atkin; Heinz-Josef Lenz; Henry T Lynch; Bruce Minsky; Bernard Nordlinger; Naureen Starling
Journal:  Lancet       Date:  2010-03-20       Impact factor: 79.321

Review 4.  Gastrointestinal radiation injury: prevention and treatment.

Authors:  Abobakr K Shadad; Frank J Sullivan; Joseph D Martin; Laurence J Egan
Journal:  World J Gastroenterol       Date:  2013-01-14       Impact factor: 5.742

5.  Normal tissue protection for improving radiotherapy: Where are the Gaps?

Authors:  Pataje G S Prasanna; Helen B Stone; Rosemary S Wong; Jacek Capala; Eric J Bernhard; Bhadrasain Vikram; C N Coleman
Journal:  Transl Cancer Res       Date:  2012-06       Impact factor: 1.241

6.  Non-CpG island promoter hypomethylation and miR-149 regulate the expression of SRPX2 in colorectal cancer.

Authors:  Bodil Øster; Lene Linnet; Lise Lotte Christensen; Kasper Thorsen; Halit Ongen; Emmanouil T Dermitzakis; Juan Sandoval; Sebastian Moran; Manel Esteller; Torben F Hansen; Philippe Lamy; Søren Laurberg; Torben F Ørntoft; Claus L Andersen
Journal:  Int J Cancer       Date:  2012-11-21       Impact factor: 7.396

Review 7.  Colorectal cancer.

Authors:  Hermann Brenner; Matthias Kloor; Christian Peter Pox
Journal:  Lancet       Date:  2013-11-11       Impact factor: 79.321

Review 8.  Inflammatory bowel disease and colon cancer.

Authors:  Noor Jawad; Natalie Direkze; Simon J Leedham
Journal:  Recent Results Cancer Res       Date:  2011

9.  Human epididymis protein-4 (HE-4): a novel cross-class protease inhibitor.

Authors:  Nirmal Chhikara; Mayank Saraswat; Anil Kumar Tomar; Sharmistha Dey; Sarman Singh; Savita Yadav
Journal:  PLoS One       Date:  2012-11-05       Impact factor: 3.240

10.  HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.

Authors:  J R Ribeiro; C Schorl; N Yano; N Romano; K K Kim; R K Singh; R G Moore
Journal:  J Ovarian Res       Date:  2016-05-17       Impact factor: 4.234

View more
  3 in total

1.  MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro.

Authors:  Lisa Svartdal Normann; Miriam Ragle Aure; Suvi-Katri Leivonen; Mads Haugland Haugen; Vesa Hongisto; Vessela N Kristensen; Gunhild Mari Mælandsmo; Kristine Kleivi Sahlberg
Journal:  Sci Rep       Date:  2021-05-25       Impact factor: 4.379

2.  miR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy.

Authors:  Lisa Svartdal Normann; Mads Haugland Haugen; Miriam Ragle Aure; Vessela N Kristensen; Gunhild Mari Mælandsmo; Kristine Kleivi Sahlberg
Journal:  Breast Cancer (Dove Med Press)       Date:  2022-03-01

3.  miR-149 inhibits cell proliferation and enhances chemosensitivity by targeting CDC42 and BCL2 in neuroblastoma.

Authors:  Fengxia Mao; Ju Zhang; Xinru Cheng; Qianya Xu
Journal:  Cancer Cell Int       Date:  2019-12-27       Impact factor: 5.722

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.